ClinicalTrials.gg
Active, not recruitingNCT07936955MICROCODEUpdated Nov 13, 2026

Multispectral Optoacoustic Imaging (MSOT) to Investigate Cerebrovascular Disease

An observational study in Stroke, Vasculitis and Cerebrovascular Disease, sponsored by University of Zurich. Active, not recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by University of Zurich · Observational

Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
64
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies in Stroke by University of Zurich — 6 open to participants now, 8 under way, none of them phase 3. Stroke · University of Zurich.

Enrollment
9th of 13
64 · median 98
Started
2021
the only one that year
Observational
13 of 26
4 open now
Registered
26th of 26
by date

Among the 26 studies in Stroke by University of Zurich, this one is the 9th largest by enrollment of the 13 observational ones that give a count, is the only one that started in 2021, is one of 13 observational ones, and was the 26th registered.

Stroke

8,269 studies on the registry are indexed under Stroke; 2,062 are open to participants now.

Browse Stroke studies →

Open to participants now

6 of the 26 studies in Stroke by University of Zurich are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 696 (49%) set no upper age limit and 282 (20%) stop at 75 or younger; 77 take children under 18; 196 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Stroke by University of Zurich, or all of them as a file.
02

Study summary

Stenosis of the internal carotid artery (ICA) is a common cause of ischemic stroke. Current clinical guidelines focus primarily on the degree of stenosis to determine treatment strategies, such as medical management, endovascular stenting, or surgical endarterectomy. However, the morphology and tissue composition of plaques are increasingly recognized as critical factors for stroke risk, as even mild-to-moderate stenosis may harbor dangerous, vulnerable plaques at risk of rupture. Conventional imaging modalities, such as duplex sonography, provide limited information regarding specific plaque characteristics and vessel wall inflammation, making the discrimination between atherosclerotic and inflammatory diseases a persistent diagnostic challenge. This study utilizes multi-spectral optoacoustic tomography (MSOT), a non-invasive imaging approach that combines ultrasound with laser technology to visualize disease-specific tissue biomarkers. MSOT offers the advantage of assessing specific tissue components, including lipid content, water, collagen, and oxygenation status (oxy- and deoxyhemoglobin), which serve as key indicators of plaque instability, vascularization, and inflammation.

The primary goal of this project is to evaluate the clinical utility of MSOT biomarker signals in characterising carotid plaques and inflammatory vessel wall changes. Investigators aim to find a definitive relation between these tissue-specific MSOT signals within the carotid artery, carotid plaques, and the superficial temporal artery, and relate them to the type (atherosclerosis versus inflammation) and severity of cardiovascular and cerebrovascular disease. The study encompasses both patients with manifest cardiovascular disease and healthy subjects with cardiovascular risk factors to explore applications in both advanced disease characterization and primary prevention.

Read the detailed description

Stenosis of the internal carotid artery (ICA) is a common cause of ischemic stroke. Treatment guidelines were established in the 1990s from the results of the large North American Symptomatic Carotid Endarterectomy Trial (NASCET) and the European Carotid Surgery Trial (ECST). Current recommendations for the management of ICA stenosis focus on stenosis degree and include medical treatment, endovascular carotid artery stenting, as well as surgical carotid endarterectomy. Briefly, if stenosis degree approaches 70%, surgical or endovascular treatment may be indicated. However, over the last 30 years, standard medical care has dramatically improved, and decision-making in cases of ICA stenosis is becoming more complex. The relevance of morphology and composition of plaques for stroke risk in ICA stenosis patients is increasingly recognized. Accordingly, even a stenosis degree of 40% or 50% may harbor a dangerous plaque at risk of rupture.

Duplex sonography is a state-of-the-art imaging modality used to assess ICA stenosis in patients with stroke or patients at risk of stroke. Although it is a very powerful and versatile method, it can only extract few characteristics of the plaque and the associated vessel wall. Furthermore, inflammatory changes of the vessel wall are difficult to assess with duplex sonography or other imaging methods such as Magnetic Resonance Imaging (MRI). Such inflammation is involved in atherosclerotic plaque development and may indicate a vulnerable plaque. At the same time, inflammation of the vessel wall is pathognomonic for vasculitis of the nervous system. The discrimination of atherosclerotic from inflammatory disease remains a challenge in stroke diagnosis and treatment.

The goal of the current project is to characterize ICA plaques or inflammatory vessel wall changes in patients with cardiovascular disease and healthy subjects with cardiovascular risk factors. Multispectral Optoacoustic Tomography (MSOT) is a non-invasive approach for carotid plaque visualization and characterization. MSOT has the unique advantage of imaging disease-specific biomarkers in addition to conventional ultrasound methods. For carotid imaging, specific assessment of lipid content and oxygenation state are particularly interesting, since lipid accumulation and plaque vascularization are key indicators of plaque formation and advancement towards instability and stroke risk.

The investigators aim at: 1) characterizing the vulnerable carotid plaque, 2) differentiating atherosclerotic from inflammatory vessel wall changes, and 3) characterizing subclinical pathology (lipid accumulation, inflammation) in the vessel wall of patients with vascular risk factors, but without stroke (primary prevention). The MSOT Acuity is a CE-certified device to detect and visualize photo-absorbers in soft tissue.

The hypothesis is that lipid, water, oxy-/deoxyhemoglobin content, and collagen signals strongly relate to the type (atherosclerosis versus inflammation) and severity of cerebrovascular disease. The primary objective is to find a relation of the new MSOT biomarker signals (lipid, water, oxy-/deoxyhemoglobin, and collagen content) of the carotid artery/plaque and the superficial temporal artery (STA) to the type (atherosclerosis versus inflammation) and severity of cardiovascular disease.

03

Conditions studied

  • Stroke
  • Vasculitis
  • Cerebrovascular Disease

Keywords

  • stroke
  • arteritis temporalis
  • cerebrovascular disease
  • MSOT
  • Multispectral optoacoustic tomography
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population consists of hospitalized inpatients and ambulatory outpatients presenting to specialized neurological, vascular, or ophthalmological departments, alongside healthy volunteer controls. It encompasses individuals undergoing clinical evaluation for carotid atherosclerosis or suspected giant cell arteritis, reflecting a real-world clinical cohort referred for advanced vascular imaging.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • written
  • patient with carotid artery plaques (detected by ultrasound) either hospitalized because of ischemic symptoms or asymptomatic (ambulatory).
  • patients with suspicion of giant cell arteritis (from clinical or ophthalmological diagnosis) either hospitalized because of symptoms or ambulatory, regardless of treatment with
  • healthy subjects

Exclusion criteria

Exclusion Criteria:

  • pregnant patients
  • Participants unable to tolerate MSOT measurements (approx. 15min with laser protection goggles)
  • Patients not available for at least first follow up after 3 months, or with severe comorbidity likely to interfere with a follow up at 3 months
  • Tattoos, , Skin lesions or Fitzpatrick skin type I, V and VI at the site of MSOT investigation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
64 participants (actual)
Patient registry
No

Groups and cohorts

  • Healthy

    Healthy subjects without plaques in the extra cranial carotid arteries who haven't suffered from stroke yet.

  • Plaque

    Patients with plaques in the extra cranial carotid arteries,, who haven't suffered from stroke before enrollment.

  • Stroke

    Patients with plaques in the extra cranial carotid arteries,, who have suffered from stroke before enrollment

  • STA

    Patients who have been diagnosed with or suspected of suffering from giant cell arteritis in the superficial temporal arteries before enrollment.

06

What researchers measure

Primary outcomes

  1. Multispectral optoacoustic tomography (MSOT) signal intensity of carotid tissue components

    Optoacoustic signal intensity of targeted tissue components (lipid content, water content, oxyhemoglobin, deoxyhemoglobin, and collagen) measured in arbitrary spectral units (AU) within the carotid artery wall and atherosclerotic plaques to characterize tissue composition.

    Time frame: Baseline up to 2 years follow-up

  2. National Institutes of Health Stroke Scale (NIHSS) score

    Neurological impairment assessed using the National Institutes of Health Stroke Scale (NIHSS). The score ranges from 0 to 42, where 0 indicates normal neurological function and 42 represents severe neurological impairment. Higher scores indicate worse outcomes.

    Time frame: Baseline up to 2 years follow-up

  3. Modified Rankin Scale (mRS) score

    Degree of disability or dependence in daily activities measured using the modified Rankin Scale (mRS). The scale ranges from 0 (no symptoms at all) to 6 (death). Higher scores indicate worse functional outcomes.

    Time frame: Baseline up to 2 years follow-up

  4. Perceived Stress Scale-10 (PSS-10) score

    Assessment of the perception of stress measured using the Perceived Stress Scale-10 (PSS-10). The score ranges from 0 to 40, calculated by summing item responses. Higher scores represent higher levels of perceived stress.

    Time frame: Baseline and 2-year follow-up

Secondary outcomes

  1. Correlation between MSOT biomarkers and routine carotid ultrasound findings

    Correlation coefficient between MSOT signal intensities (lipid content, tissue oxygenation, collagen) and conventional ultrasound parameters (plaque echogenicity, stenosis degree according to NASCET criteria) to assess imaging concordance.

    Time frame: Baseline and 2-year follow-up

  2. Correlation between MSOT biomarkers and histopathological biopsy characteristics

    Correlation between MSOT tissue components (lipid content, inflammation signals) and histopathological presence of intraplaque hemorrhage, lipid-rich necrotic core, or giant cell arteritis markers from resected carotid plaque or superficial temporal artery (STA) biopsy specimens.

    Time frame: Baseline and 2-year follow-up

  3. Correlation between MSOT biomarker signals and serum lipid levels

    Assessment of the correlation between MSOT optoacoustic signal intensities (lipid content) and fasting serum lipid levels (total cholesterol, LDL-C, HDL-C, and triglycerides in mmol/L).

    Time frame: Baseline up to 2-year follow-up

  4. Correlation between MSOT biomarker signals and laboratory inflammatory markers in temporal arteritis

    Assessment of the correlation between MSOT optoacoustic signal intensities of the superficial temporal artery (STA) and systemic laboratory inflammatory parameters (C-reactive protein in mg/L and erythrocyte sedimentation rate in mm/h).

    Time frame: Baseline up to 2-year follow-up

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Feb 2026, 57 months.

Of 837 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's 57 months is above that.

Counting every sponsor, half of 899 studies reached it within 40 months; a quarter within 18 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2026
First posted
Nov 13, 2026
StartActual
Apr 19, 2021
Primary completionActual
Feb 10, 2026
CompletionEst.
Nov 1, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07936955
Responsible party
Sponsor
First posted
Nov 13, 2026
Start date
Apr 19, 2021
Primary completion
Feb 10, 2026
Completion
Nov 1, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Susanne Wegener, Prof. Dr. med.
principal investigator · University hospital of Zurich, Department of Neurology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion